Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATLANTIS maintenance targeted therapy trial in metastatic urothelial cancer
2015-003249-25Phase 2Unknown
- Sponsor
- NHS Greater Glasgow and Clyde
- Start
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of cabozantinib, rucaparib and enzalutamide in transitional cell carcinoma (TCC) and bladder adenocarcinoma (4 arms), sponsored by NHS Greater Glasgow and Clyde. Primary endpoint: progression-free survival. Status: unknown.
02
Drugs
cabozantinibrucaparibenzalutamide
03
Conditions
transitional cell carcinoma (TCC)bladder adenocarcinoma
Beyond the preview
Go deeper on 2015-003249-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003249-25.